Medical treatment of primary pulmonary hypertension: A bridge to transplantation?

doi:10.1016/S0002-9149(99)80385-3

The American Journal of Cardiology

Volume 75, Issue 3, Supplement 1, 19 January 1995, Pages 63A-66A

https://doi.org/10.1016/S0002-9149(99)80385-3 Get rights and content

Primary pulmonary hypertension is a progressive disease with a mean survival of <3 years from the time of diagnosis. Recent advances in the medical management have shown that some patients may have an extremely good outcome depending on the response to high doses of calcium antagonists. Anticoagulants are also associated with improved survival, and prostacyclin is showing great promise in patients who are refractory to conventional therapy. At the same time, lung transplantation has developed into a viable treatment option for patients who remain symptomatic and deteriorate on medical management. The role of the various medical treatment modalities, and the ideal timing of lung transplantation, is an issue that is continuing to evolve as improvements in all treatments develop. The cost and availability of the various treatments will likely affect the selection of treatments in individual patients as well.

References (29)

FarberHW et al.
Fatal outcome following nifedipine for primary pulmonary hypertension
Chest
(1983)
AromatorioGJ et al.
Hypotension and sinus arrest with nifedipine in pulmonary hypertension
Chest
(1985)
RubinLJ
ACCP Consensus Statement: primary pulmonary hypertension
Chest
(1993)
SametP et al.
Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension
Am Heart J
(1963)
RozkovecA et al.
Factors that influence the outcome of primary pulmonary hypertension
Br Heart J
(1986)
RichS et al.
Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension
Am J Med
(1984)
D'AlonzoGE et al.
Survival in patients with primary pulmonary hypertension: results from a National Prospective Registry
Ann Intern Med
(1991)
WoodP
Pulmonary hypertension with special reference to the vasoconstrictive factor
Br Heart J
(1958)
RaoBNS et al.
Primary pulmonary hypertension in a child, Response to pharmacologic agents
Circulation
(1969)
GraverRF et al.
Tolazoline hydrochloride (priscoline): an effective pulmonary vasodilator
Am Heart J
(1961)

ReevesJT et al.

The case for treatment of selected patients with primary pulmonary hypertension

Am Rev Respir Dis

(1986)

CohenML et al.

Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension

Ann Intern Med

(1981)

KronzonI et al.

Adverse effect of hydralazine in patients with primary pulmonary hypertension

JAMA

(1982)

RichS et al.

The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension

Circulation

(1985)

Cited by (44)

Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease
2002, Chest
To determine the utility of the ECG for predicting clinical status in adults with primary pulmonary hypertension (PPH) or pulmonary arterial hypertension (PAH) secondary to collagen vascular disease.
Retrospective study.
Outpatient clinic in a tertiary referral center.
Adult outpatients with PPH or PAH secondary to collagen vascular disease who underwent electrocardiography within 30 days of undergoing right-heart catheterization, echocardiography, and 6-min walk testing.
None.
The following measurements were recorded from each ECG: P-wave amplitude in lead II; mean frontal QRS axis; QRS duration; R-wave and S-wave deflections in leads I and V6; and the T-wave configurations in the precordial leads. These ECG variables were correlated with hemodynamic variables, RV size, and exercise capacity. Of the 61 patients included in this study, 56 (92%) were women. Eight of 61 patients (13%) had normal findings on ECGs. There was no significant difference in the demographics or hemodynamics when comparing groups with normal vs abnormal ECGs. All ECG parameters had no more than moderate correlation with hemodynamic variables, ventricular size measured by echocardiogram, and exercise capacity as measured by a 6-min walk. The best correlation was between mean the frontal QRS axis and cardiac index (r = −0.46).
The ECG is an inadequate screening tool to rule out the presence of clinically relevant pulmonary hypertension, either primary or secondary to collagen vascular disease. The mean frontal QRS axis correlated best with the severity of hemodynamic impairment.
Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE<inf>1</inf>, nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension
2001, Prostaglandins Leukotrienes and Essential Fatty Acids
Acute hemodynamic effects of beraprost sodium were tested in a canine vasoconstrictive pulmonary hypertension model induced by the continuous infusion of U-46619, a thromboxane A₂mimetic. The effects of beraprost were compared with those of prostaglandin E₁, nitroglycerin and nifedipine. Beraprost and nitroglycerin decreased pulmonary arterial pressure. On the other hand, prostaglandin E₁and nifedipine increased pulmonary arterial pressure. All drugs except nitroglycerin increased cardiac output and decreased pulmonary vascular resistance. Beraprost was selective to pulmonary circulation, while nitroglycerin, prostaglandin E₁, and nifedipine showed poor selectivity for the pulmonary vasculature. These results suggest that the vasodilative effect of beraprost is the most selective for the pulmonary circulation among these four vasodilators.
Initial dual oral combination therapy in pulmonary arterial hypertension
2016, European Respiratory Journal
Targeted approaches to the treatment of pulmonary hypertension
2012, Therapeutic Advances in Respiratory Disease
Pulmonary hypertension: Clinical presentation, diagnosis, treatment, and dana point world symposium highlights
2011, Current Respiratory Medicine Reviews
New approaches to the treatment of pulmonary hypertension: From bench to bedside
2010, Cardiology in Review

View all citing articles on Scopus

View full text

Medical treatment of primary pulmonary hypertension: A bridge to transplantation?

Chest

Chest

Chest

Am Heart J

Factors that influence the outcome of primary pulmonary hypertension

Br Heart J

Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension

Am J Med

Survival in patients with primary pulmonary hypertension: results from a National Prospective Registry

Ann Intern Med

Pulmonary hypertension with special reference to the vasoconstrictive factor

Br Heart J

Primary pulmonary hypertension in a child, Response to pharmacologic agents

Circulation

Tolazoline hydrochloride (priscoline): an effective pulmonary vasodilator

Am Heart J

The case for treatment of selected patients with primary pulmonary hypertension

Am Rev Respir Dis

Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension

Ann Intern Med

Adverse effect of hydralazine in patients with primary pulmonary hypertension

JAMA

The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension

Circulation